# A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

Source: https://onco.cc/trials/nct03706690/  
OnCo record `nct03706690` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Durvalumab in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients is a phase 3 interventional study registered as NCT03706690 by AstraZeneca, with 407 participants enrolled, started 2018-11-27 and due to reach its primary completion in 2024-06-23. Interventions recorded: Durvalumab. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: PACIFIC-5
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03706690
- Phase: 3
- Setting: A Phase III, Randomised,Double-Blind,Placebo-Controlled,Study of Durvalumab as Consolidation Therapy in Patients With Locally Advanced,Unresectable NSCLC, Who Have Not Progressed Following Definitive, Platinum-Based Chemoradiation Therapy
- Sponsor: AstraZeneca
- Enrolled: 407
- Outcomes: Progression-Free Survival (PFS) (Modified Intent-to-Treat [mITT] Set): Durvalumab 14 months vs Placebo 6.5 months, HR 0.75; Overall Survival (OS), ITT set: Durvalumab 38.4 months vs Placebo 32.5 months, HR 0.87; Objective Response Rate (ORR), ITT set: Durvalumab 27.1% vs Placebo 19.7%

## Sources

- ClinicalTrials.gov NCT03706690: https://clinicaltrials.gov/study/NCT03706690

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Unresectable stage III non-small-cell lung cancer](https://onco.cc/cancers/stage-iii-unresectable-nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- key papers: [PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy](https://onco.cc/key-papers/paper-nct03706690-j-hematol-oncol-2025/)

---
JSON: https://onco.cc/api/v1/entities/nct03706690.json